Morgan Stanley Adjusts Hengan International's Price Target to HK$23, Keeps Market-Perform Rating

Stock News06-24

According to a research report, Morgan Stanley stated that the tissue paper business of Hengan International (01044) should remain the primary growth driver, benefiting from volume growth and market share gains. However, revenue growth is likely to stay moderate due to pressure on average selling prices from online and new retail channels. The firm has consequently lowered the company's target price by 4.2% from HK$24 to HK$23, reflecting reduced government subsidies and tax rebates.

Morgan Stanley views the stock's valuation as not expensive. With stable cash generation capabilities, the dividend yield should provide support for the share price. Nevertheless, it would be difficult to justify a higher valuation multiple unless revenue growth accelerates noticeably or clearer evidence emerges of a sustained recovery in the hygiene products segment. The investment rating of "Market-Perform" is maintained.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment